Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...

Tsukuba, Japan—T-follicular helper (TFH) lymphoma is a blood cancer subgroup that continues to demonstrate a generally poor prognosis, with no standard treatment established to date. Although specific ...

Tsukuba, Japan—Follicular lymphoma is a common and recurrent form of malignant lymphoma. Although the role of T cells (a type of lymphocyte) in its development has been suggested, the diversity and ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma. Treatment with the CAR T-cell therapy Yescarta ...

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

For some people, treating follicular lymphoma involves active surveillance until severe symptoms develop. For others, chemoimmunotherapy, radiation therapy, or targeted treatments may be necessary.